Levamisole in rheumatoid arthritis: a comparison with D-penicillamine.
Levamisole (150 mg 3 days/week) was compared with D-penicillamine (250 mg increments at 2--3 monthly intervals) in a single, blind independent observer trial of 1 years' duration in 32 patients with rheumatoid arthritis. The clinical responses, evident after 3 months, were comparable and significant. Six patients on levamisole and 4 on penicillamine withdrew due to side effects. In the subsequent open study 3 of 8 patients continued on levamisole for up to 4 years, while 6 of 9 remained on penicillamine. The findings are compared with those of other trials.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007978:Levamisole / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D007978:Levamisole; D010396:Penicillamine